2025 Q4 -tulosraportti

49 päivää sitten

13,5008 CAD/osake

Viimeisin osinko

Tarjoustasot

Määrä

Osto

500

Myynti

Määrä

214

Viimeisimmät kaupat

Aika	Hinta	Määrä	Ostaja	Myyjä
-		-	-	-

Ylin

13

VWAP

11,84

Alin

10,15

VaihtoMäärä

1,3 164 636

VWAP

11,84

Ylin

13

Alin

10,15

VaihtoMäärä

1,3 164 636

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Seuraava tapahtuma
2026 Q1 -tulosraportti	10.12. 7 päivää

Menneet tapahtumat
2025 Q4 -tulosraportti	15.10.
2025 Q3 -tulosraportti	16.6.
2025 Q2 -tulosraportti	12.3.
2025 Q1 -tulosraportti	16.12.2024
2024 Q4 -tulosraportti	28.10.2024

Datan lähde: FactSet

Asiakkaat katsoivat myös

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

00 Dunken
4.11.
·
00 Dunken
4.11.
·
Good news again today. It will be exciting to see what happens during the week and especially on Friday.
Benedichte
4.11.
·
Benedichte
4.11.
·
What's happening this week? I see it has been high today :)
freic0
27.10.
freic0
27.10.
Why is BriaCell down almost 7% premarket? Will it plummet today or is it just regular Vol after it rose a little pre weekend?
NSTT
27.10.
·
NSTT
27.10.
·
Bids are increased shorts, biotech volatility and perhaps supply chain challenges.
freic0
27.10.
·
freic0
27.10.
·
Thanks
Drill
24.10.
·
Drill
24.10.
·
Over the course of three days in October 2025, BriaCell published four press releases that together demonstrate significant progress and strategic initiatives: • 20 Oct 2025: Phase 3 biomarker data at ESMO – BriaCell presented promising biomarker results from its ongoing Phase 3 study (Bria-IMT™ + immune checkpoint inhibitor) in metastatic breast cancer. Data shows that a certain immunological biomarker (NLR ratio) is linked to longer disease control, and no new safety concerns have been observed. • 21 Oct 2025 (morning): Expansion of clinical trial sites – BriaCell announced that 79 clinics in 23 states are now participating in the Phase 3 study, including prestigious cancer centers such as Dartmouth, Cedars-Sinai, and Emory. This is expected to accelerate patient recruitment and means that top-line results could come as early as H1 2026. • 21 Oct 2025 (13:10): Collaboration with MSK – BriaCell announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the development of Bria-OTS+™, the next-generation personalized “off-the-shelf” immunotherapy platform. MSK is assisting with manufacturing, IND application, and clinical design for a planned Phase 1 study with Bria-BRES+™ (for breast cancer). • 22 Oct 2025: Positive DSMB recommendation – An independent Data Safety Monitoring Board (DSMB) gave its fourth consecutive positive recommendation for the Phase 3 study after reviewing safety data. No safety concerns have been noted and the study continues without changes, which further confirms the good safety profile of the Bria-IMT regimen. These news items paint a comprehensive picture of a company that is both reaching important milestones in its main study and investing in future innovations. Together, these news items indicate that BriaCell is on track for a potential breakthrough with its Phase 3 study (top-line results in the near future) and that the company is positioning itself as a future key player in cancer immunotherapy through technological advancements and collaborations. It manages both the present (driving Phase 3 to completion) and the future (new products, partnerships). For the company, this means an increased probability of both regulatory success (FDA approval of Bria-IMT if results are good, thanks to Fast Track and robust data) and commercial success (building a network of clinics and new treatment concepts to be competitive long-term). The common thread is clear: focus on patients' needs – from identifying which patients can be helped most, to engaging clinics close to patients, further to developing the next generation that can help even more, all while safety is prioritized. BriaCell shows with these coordinated releases that they are executing on their plan and communicating successes on multiple fronts, which is often a sign of a company with momentum. If nothing unforeseen occurs, everything indicates that the Phase 3 study will be able to be completed in the near future and give BriaCell the chance to transition from clinical stage to a market-approved drug with an innovative immunotherapy for severely ill breast cancer patients – while also planning the next steps to stay at the forefront even thereafter. Risks to consider: • Competition in immunotherapy • Capital requirements for continued development • Regulatory uncertainty regarding biomarker-based selection
00 Dunken
23.10.
·
00 Dunken
23.10.
·
Come on chat, we are red hot today. All the news in one week, we should gain at least 50%. There's a long way to the top, but we'll hit it 🔥🔥🔥
00 Dunken
16.10.
·
00 Dunken
16.10.
·
Huge k-10 from Bctx. Let's get back on track 🚀
freic0
16.10.
freic0
16.10.
Just got in. Thanks for the comment
00 Dunken
20.10.
·
00 Dunken
20.10.
·
WRD, MLTX, PONY, GRRR, SOUN. I absolutely love SOUN and Grrr, and they both need a huge breakout. SOUN has certainly gone up a lot in the last month, but year to date they are still not much of a plus

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset ja analyysit

Ei uutisia tällä hetkellä

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

49 päivää sitten

13,5008 CAD/osake

Viimeisin osinko

Uutiset ja analyysit

Ei uutisia tällä hetkellä

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

00 Dunken
4.11.
·
00 Dunken
4.11.
·
Good news again today. It will be exciting to see what happens during the week and especially on Friday.
Benedichte
4.11.
·
Benedichte
4.11.
·
What's happening this week? I see it has been high today :)
freic0
27.10.
freic0
27.10.
Why is BriaCell down almost 7% premarket? Will it plummet today or is it just regular Vol after it rose a little pre weekend?
NSTT
27.10.
·
NSTT
27.10.
·
Bids are increased shorts, biotech volatility and perhaps supply chain challenges.
freic0
27.10.
·
freic0
27.10.
·
Thanks
Drill
24.10.
·
Drill
24.10.
·
Over the course of three days in October 2025, BriaCell published four press releases that together demonstrate significant progress and strategic initiatives: • 20 Oct 2025: Phase 3 biomarker data at ESMO – BriaCell presented promising biomarker results from its ongoing Phase 3 study (Bria-IMT™ + immune checkpoint inhibitor) in metastatic breast cancer. Data shows that a certain immunological biomarker (NLR ratio) is linked to longer disease control, and no new safety concerns have been observed. • 21 Oct 2025 (morning): Expansion of clinical trial sites – BriaCell announced that 79 clinics in 23 states are now participating in the Phase 3 study, including prestigious cancer centers such as Dartmouth, Cedars-Sinai, and Emory. This is expected to accelerate patient recruitment and means that top-line results could come as early as H1 2026. • 21 Oct 2025 (13:10): Collaboration with MSK – BriaCell announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the development of Bria-OTS+™, the next-generation personalized “off-the-shelf” immunotherapy platform. MSK is assisting with manufacturing, IND application, and clinical design for a planned Phase 1 study with Bria-BRES+™ (for breast cancer). • 22 Oct 2025: Positive DSMB recommendation – An independent Data Safety Monitoring Board (DSMB) gave its fourth consecutive positive recommendation for the Phase 3 study after reviewing safety data. No safety concerns have been noted and the study continues without changes, which further confirms the good safety profile of the Bria-IMT regimen. These news items paint a comprehensive picture of a company that is both reaching important milestones in its main study and investing in future innovations. Together, these news items indicate that BriaCell is on track for a potential breakthrough with its Phase 3 study (top-line results in the near future) and that the company is positioning itself as a future key player in cancer immunotherapy through technological advancements and collaborations. It manages both the present (driving Phase 3 to completion) and the future (new products, partnerships). For the company, this means an increased probability of both regulatory success (FDA approval of Bria-IMT if results are good, thanks to Fast Track and robust data) and commercial success (building a network of clinics and new treatment concepts to be competitive long-term). The common thread is clear: focus on patients' needs – from identifying which patients can be helped most, to engaging clinics close to patients, further to developing the next generation that can help even more, all while safety is prioritized. BriaCell shows with these coordinated releases that they are executing on their plan and communicating successes on multiple fronts, which is often a sign of a company with momentum. If nothing unforeseen occurs, everything indicates that the Phase 3 study will be able to be completed in the near future and give BriaCell the chance to transition from clinical stage to a market-approved drug with an innovative immunotherapy for severely ill breast cancer patients – while also planning the next steps to stay at the forefront even thereafter. Risks to consider: • Competition in immunotherapy • Capital requirements for continued development • Regulatory uncertainty regarding biomarker-based selection
00 Dunken
23.10.
·
00 Dunken
23.10.
·
Come on chat, we are red hot today. All the news in one week, we should gain at least 50%. There's a long way to the top, but we'll hit it 🔥🔥🔥
00 Dunken
16.10.
·
00 Dunken
16.10.
·
Huge k-10 from Bctx. Let's get back on track 🚀
freic0
16.10.
freic0
16.10.
Just got in. Thanks for the comment
00 Dunken
20.10.
·
00 Dunken
20.10.
·
WRD, MLTX, PONY, GRRR, SOUN. I absolutely love SOUN and Grrr, and they both need a huge breakout. SOUN has certainly gone up a lot in the last month, but year to date they are still not much of a plus

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä

Osto

500

Myynti

Määrä

214

Viimeisimmät kaupat

Aika	Hinta	Määrä	Ostaja	Myyjä
-		-	-	-

Ylin

13

VWAP

11,84

Alin

10,15

VaihtoMäärä

1,3 164 636

VWAP

11,84

Ylin

13

Alin

10,15

VaihtoMäärä

1,3 164 636

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Asiakkaat katsoivat myös

Yhtiötapahtumat

Seuraava tapahtuma
2026 Q1 -tulosraportti	10.12. 7 päivää

Menneet tapahtumat
2025 Q4 -tulosraportti	15.10.
2025 Q3 -tulosraportti	16.6.
2025 Q2 -tulosraportti	12.3.
2025 Q1 -tulosraportti	16.12.2024
2024 Q4 -tulosraportti	28.10.2024

Datan lähde: FactSet

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

49 päivää sitten

Uutiset ja analyysit

Ei uutisia tällä hetkellä

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Seuraava tapahtuma
2026 Q1 -tulosraportti	10.12. 7 päivää

Menneet tapahtumat
2025 Q4 -tulosraportti	15.10.
2025 Q3 -tulosraportti	16.6.
2025 Q2 -tulosraportti	12.3.
2025 Q1 -tulosraportti	16.12.2024
2024 Q4 -tulosraportti	28.10.2024

Datan lähde: FactSet

Tuotteita joiden kohde-etuutena tämä arvopaperi

13,5008 CAD/osake

Viimeisin osinko

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

00 Dunken
4.11.
·
00 Dunken
4.11.
·
Good news again today. It will be exciting to see what happens during the week and especially on Friday.
Benedichte
4.11.
·
Benedichte
4.11.
·
What's happening this week? I see it has been high today :)
freic0
27.10.
freic0
27.10.
Why is BriaCell down almost 7% premarket? Will it plummet today or is it just regular Vol after it rose a little pre weekend?
NSTT
27.10.
·
NSTT
27.10.
·
Bids are increased shorts, biotech volatility and perhaps supply chain challenges.
freic0
27.10.
·
freic0
27.10.
·
Thanks
Drill
24.10.
·
Drill
24.10.
·
Over the course of three days in October 2025, BriaCell published four press releases that together demonstrate significant progress and strategic initiatives: • 20 Oct 2025: Phase 3 biomarker data at ESMO – BriaCell presented promising biomarker results from its ongoing Phase 3 study (Bria-IMT™ + immune checkpoint inhibitor) in metastatic breast cancer. Data shows that a certain immunological biomarker (NLR ratio) is linked to longer disease control, and no new safety concerns have been observed. • 21 Oct 2025 (morning): Expansion of clinical trial sites – BriaCell announced that 79 clinics in 23 states are now participating in the Phase 3 study, including prestigious cancer centers such as Dartmouth, Cedars-Sinai, and Emory. This is expected to accelerate patient recruitment and means that top-line results could come as early as H1 2026. • 21 Oct 2025 (13:10): Collaboration with MSK – BriaCell announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the development of Bria-OTS+™, the next-generation personalized “off-the-shelf” immunotherapy platform. MSK is assisting with manufacturing, IND application, and clinical design for a planned Phase 1 study with Bria-BRES+™ (for breast cancer). • 22 Oct 2025: Positive DSMB recommendation – An independent Data Safety Monitoring Board (DSMB) gave its fourth consecutive positive recommendation for the Phase 3 study after reviewing safety data. No safety concerns have been noted and the study continues without changes, which further confirms the good safety profile of the Bria-IMT regimen. These news items paint a comprehensive picture of a company that is both reaching important milestones in its main study and investing in future innovations. Together, these news items indicate that BriaCell is on track for a potential breakthrough with its Phase 3 study (top-line results in the near future) and that the company is positioning itself as a future key player in cancer immunotherapy through technological advancements and collaborations. It manages both the present (driving Phase 3 to completion) and the future (new products, partnerships). For the company, this means an increased probability of both regulatory success (FDA approval of Bria-IMT if results are good, thanks to Fast Track and robust data) and commercial success (building a network of clinics and new treatment concepts to be competitive long-term). The common thread is clear: focus on patients' needs – from identifying which patients can be helped most, to engaging clinics close to patients, further to developing the next generation that can help even more, all while safety is prioritized. BriaCell shows with these coordinated releases that they are executing on their plan and communicating successes on multiple fronts, which is often a sign of a company with momentum. If nothing unforeseen occurs, everything indicates that the Phase 3 study will be able to be completed in the near future and give BriaCell the chance to transition from clinical stage to a market-approved drug with an innovative immunotherapy for severely ill breast cancer patients – while also planning the next steps to stay at the forefront even thereafter. Risks to consider: • Competition in immunotherapy • Capital requirements for continued development • Regulatory uncertainty regarding biomarker-based selection
00 Dunken
23.10.
·
00 Dunken
23.10.
·
Come on chat, we are red hot today. All the news in one week, we should gain at least 50%. There's a long way to the top, but we'll hit it 🔥🔥🔥
00 Dunken
16.10.
·
00 Dunken
16.10.
·
Huge k-10 from Bctx. Let's get back on track 🚀
freic0
16.10.
freic0
16.10.
Just got in. Thanks for the comment
00 Dunken
20.10.
·
00 Dunken
20.10.
·
WRD, MLTX, PONY, GRRR, SOUN. I absolutely love SOUN and Grrr, and they both need a huge breakout. SOUN has certainly gone up a lot in the last month, but year to date they are still not much of a plus

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä

Osto

500

Myynti

Määrä

214

Viimeisimmät kaupat

Aika	Hinta	Määrä	Ostaja	Myyjä
-		-	-	-

Ylin

13

VWAP

11,84

Alin

10,15

VaihtoMäärä

1,3 164 636

VWAP

11,84

Ylin

13

Alin

10,15

VaihtoMäärä

1,3 164 636

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä